QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans
- 22 February 2001
- Vol. 19 (15-16), 2080-2091
- https://doi.org/10.1016/s0264-410x(00)00415-1
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- AIDSVAX®(MN) in Bangkok Injecting Drug Users: A Report on Safety and Immunogenicity, Including Macrophage-Tropic Virus NeutralizationAIDS Research and Human Retroviruses, 2000
- Primary Isolate Neutralization by HIV Type 1-Infected Patient Sera in the Era of Highly Active Antiretroviral TherapyAIDS Research and Human Retroviruses, 1999
- HIV-1MN Recombinant Glycoprotein 160 Vaccine-Induced Cellular and Humoral Immunity Boosted by HIV-1MN Recombinant Glycoprotein 120 VaccineAIDS Research and Human Retroviruses, 1999
- Safety Profile of Phase I and II Preventive HIV Type 1 Envelope Vaccination: Experience of the NIAID AIDS Vaccine Evaluation GroupAIDS Research and Human Retroviruses, 1997
- Safety and Immunogenicity of Env 2-3, a Human Immunodeficiency Virus Type 1 Candidate Vaccine, in Combination with a Novel Adjuvant, MTP-PE/MF59AIDS Research and Human Retroviruses, 1996
- Approaches to Augmenting the Immunogenicity of Melanoma Gangliosides: From Whole Melanoma Cells to Ganglioside‐KLH Conjugate VaccinesImmunological Reviews, 1995
- Effect of Adjuvants on Immunogenicity of MN Recombinant Glycoprotein 120 in Guinea PigsAIDS Research and Human Retroviruses, 1995
- Accessory Cell Requirements for Saponin Adjuvant-Induced Class I MHC Antigen-Restricted Cytotoxic T-LymphocytesCellular Immunology, 1994
- Adjuvants and Immune EnhancementInternational Journal of Technology Assessment in Health Care, 1994
- Human Immunodeficiency Virus (HIV-l) gp160-Specific Lymphocyte Proliferative Responses of Mononuclear Leukocytes from HIV-l Recombinant gp160 Vaccine RecipientsThe Journal of Infectious Diseases, 1991